Boehringer Ingelheim Partners with Ministry of Health to Enhance Healthcare Outcomes for Vietnamese Patients

Boehringer Ingelheim, one of the world's leading biopharmaceutical research-oriented corporations, has signed a Memorandum of Understanding with the Department of Medical Service Administration (Ministry of Health) to optimize healthcare outcomes for Vietnamese patients.

The signing ceremony took place within the framework of the 25th anniversary of Boehringer Ingelheim's presence in Vietnam, with the participation of representatives from the Ministry of Health, healthcare organizations, and media agencies.

The collaboration aims to improve diagnosis, treatment, and management of cardiovascular, renal, metabolic, pulmonary, and other non-communicable diseases, helping to reduce treatment costs, social costs, and contribute to improving the quality of life for patients.

The cooperation framework includes activities such as professional training and continuous medical education for doctors; support for diagnosis and improvement of treatment quality, disease management, and raising community awareness about diseases.

Associate Professor. Dr. Luong Ngoc Khue, Vice President of the National Medical Council, Head of Department of Medical Service Administration, welcomed and highly appreciated the collaboration of Boehringer Ingelheim, contributing to the implementation of the goal of improving the capacity and effectiveness of the Vietnamese healthcare system to better meet the healthcare needs of the entire population.

Ms. Cyndy Bautista-Galimpin, General Manager of Boehringer Ingelheim Vietnam, shared, "Boehringer Ingelheim is proud to join hands with the Vietnam Department of Medical Service Administration to promote advances in healthcare in Vietnam. This is part of our long-term commitment to contribute to addressing unmet medical needs and is in line with our purpose of Transforming Lives for Generations."

According to the the World Health Organization (WHO), non communicable diseases kill 41 million people each year or equivalent to 74% of all deaths. Of them, 77% are in low- and middle-income countries, including Vietnam1.  The number of Vietnamese with diabetes reached almost five million in 2021, equivalent to 7.1% of adults, according to the Ministry of Health2.

Within the framework of the 25th anniversary of Boehringer Ingelheim's operations in Vietnam, the company has collaborated with authorized health organizations to organize scientific congresses in Ho Chi Minh City and Hanoi in various treatment areas, including cardiovascular, respiratory, orthopedic, neurology, immunity, and oncology, with the participation of more than 1,000 doctors from hospitals nationwide.

The congress revealed two significant announcements, demonstrating the commitment to the objective of caring for the overall health of the Vietnamese population: The combination of SGLT2i and DPP4i tablet, which help medical professionals treat type 2 diabetes patients more effectively and allow patients to better control their disease; The company’s SGLT2 inhibitor product approved by the Ministry of Health for reducing the risk of cardiovascular death and hospitalization due to heart failure, bringing benefits to more patients and improving heart failure treatment in Vietnam.

In addition to Boehringer Ingelheim’s innovative medicines, the Angels Initiative is among the best examples of how Boehringer Ingelheim supports broadening patients’ access to medicine by partnering to improve stroke care. Boehringer Ingelheim is in partnership with the World Stroke Organization (WSO) and many other national stroke societies, companies, and health institutions to build an innovative network of stroke-ready hospitals and stroke centers. It has enrolled over 1,000 hospitals to serve more than 300,000 patients to date with substantially improved care in the region.

In Vietnam, Boehringer Ingelheim Vietnam is partnering with Vietnam Stroke Association (VNSA), HCM Stroke Association (HSA) and local hospitals to improve stroke care and at the end of 2022, there have been 120 hospitals joined Angels project with 98 stroke ready hospitals.To date, more than 44,000 patients in Vietnam have been positively impacted by this initiative.

Boehringer Ingelheim is also committed to Animal Health. In Vietnam, the campaign "Rabies vaccination for the community" in Long An is a continuing collaboration with the local authorities and BI’s partners to eliminate rabies in the region. This program has vaccinated more than 12,000 dogs and cats to date for the past 3 years.

B.H (Vietnam Business Forum)